Twist Bioscience 10-Qquarter ended 2025-12-31
Positive
Therapeutics demand and global supply partners lifted DNA synthesis sales; process savings widened margins, but higher commercial costs limited loss improvement.
Filed 2026-02-02 16:15 ET
Key figures · Q1 FY2026 · period ended 2025-12-31
- Revenue$103.7MYoY +16.9%QoQ +4.7%
- Operating income−$32.9MYoY +5.0%QoQ −9.9%
- Net income−$30.5MYoY +3.4%QoQ −12.4%
- Total assets$638.1MYoY +4.8%QoQ −0.6%
- Total debt$15.0MYoY 0.0%QoQ 0.0%
- Shareholders' equity$456.1MYoY 0.0%QoQ −3.6%
- Tangible book value$360.7MYoY +1.4%QoQ −4.4%
How this filing reads
- Health+0.3The $198M cash balance covers $34.8M quarterly FCF use; management expects at least one year.
- Momentum+0.4Revenue rose 16.9% and gross margin reached 52.0%, while operating loss narrowed to $32.9M.
- Outlook+0.2Management expects at least one year of funding, with therapeutics revenue rising to $37.2M.
Executive Summary
Twist Bioscience’s Q1 FY2026 revenue grew 16.9% as therapeutics demand, global supply partners and higher gene shipments lifted sales; process improvements also expanded gross margin. Those gains narrowed the operating loss, but rising commercial and corporate spending kept the company far from profitability, while operating cash use increased. Cash and short-term investments of $198M support management’s expectation of at least one year of funding, though continued losses, capital spending and expanded lease commitments make progress toward cash efficiency the key investor test.
Key Financial Highlights
| Metric | Q1 FY2026 / 12/31/2025 | Investor interpretation |
|---|---|---|
| Revenue | $104M, +16.9% Y/Y | Growth was led by DNA synthesis and protein solutions. |
| Gross profit and margin | $54.0M, +26% Y/Y; 52.0% vs 48.3% | Process savings helped sales growth translate into higher margin. |
| Operating loss | $(32.9)M vs $(34.6)M | Higher selling, general and administrative expense absorbed much of the gross-profit gain. |
| GAAP net loss / OCF / FCF | $(30.5)M / $(24.8)M / $(34.8)M | Cash use increased despite a modestly smaller net loss. |
| Cash and short-term investments | $198M fair value | Liquidity remains substantial, but ongoing cash use reduces the cushion. |
| Total assets | $638M | Includes private-company investments and acquired intangible value. |
| Total equity / tangible common equity | $456M / $361M | Tangible common equity excludes $82.2M of goodwill and $13.2M of net intangible assets. |
- Cash conversion: Q1 OCF use rose from $21.4M, while property and equipment purchases rose to $9.97M from $2.27M. Inventory, prepaid assets and lower accrued compensation contributed to working-capital outflows.
- Expense mix: R&D fell 20% to $17.1M, partly following the FY2025 sale of the DNA digital data storage business; selling, general and administrative expense rose 24% to $69.7M as personnel and outside-service costs increased.
- Stock-based compensation and dilution: Compensation was $13.3M vs $12.0M. Shares outstanding rose to 61.3M from 60.6M during the quarter, so the improved loss per share of $0.50 vs $0.53 came with a larger share base.
- Revenue mix: DNA synthesis and protein solutions grew 27.4% to $51.1M; next-generation sequencing applications grew 8.2% to $52.6M. The faster-growing category now contributes nearly half of revenue.
Business Developments
Twist attributed growth primarily to increased activity in therapeutics, global supply partners, and industry and applied markets. Therapeutics revenue rose to $37.2M from $26.8M, while global supply partners rose to $12.8M from $8.53M; diagnostics was broadly flat. Genes shipped increased 32.2% to ≈271,000, and quarterly purchasing customers rose to ≈2,538 from 2,376, indicating that growth reflected both volume and customer activity. EMEA revenue rose to $38.4M from $28.3M.
Beginning in FY2026, Twist regrouped its product revenue into DNA synthesis and protein solutions and next-generation sequencing applications, with prior-year comparisons recast. Management’s strategy is to extend its DNA-writing platform into sequencing preparation, RNA and protein-related offerings while improving utilization of its Wilsonville manufacturing facility. The faster growth of therapeutics and DNA synthesis and protein solutions is consistent with that move up the value chain, but has not yet produced operating profitability.
Risk Assessment
- Cash burn and execution: The $30.5M quarterly net loss and $34.8M FCF outflow mean Twist must improve commercial scale and manufacturing utilization before its current liquidity cushion erodes further.
- Fixed commitments: Operating lease liabilities increased to $98.1M from $75.6M following a South San Francisco lease amendment extending through 6/30/2036; capital expenditure commitments add $12.9M of spending obligations.
- Spending and dilution: Selling, general and administrative expense grew faster than revenue, while $13.3M of stock-based compensation and a rising share count increase the hurdle for per-share improvement.
- Private-investment concentration and valuation: Private-company equity investments carried at $54.3M include $53.9M with a related party; maximum exposure to loss across the related entities was $56.4M, with no investment adjustment recorded this quarter.
- Litigation: Discovery continues in a securities class action after the court partially denied Twist’s motion to dismiss; the company cannot assess the likelihood or amount of a loss.
This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: the company's 10-Ks on SEC.
Strategic Outlook and Investor Actionables
The near-term opportunity is to turn rising therapeutics demand, partner sales and process efficiencies into enough gross profit to cover expanding commercial costs. Management expects available resources to fund operations for at least one year, but sustained cash use makes the pace of improvement more consequential than revenue growth alone.
- Monitor gross margin and operating loss: Continued margin gains must outpace selling, general and administrative expense growth to establish operating leverage.
- Monitor OCF, FCF and cash balances: Lower cash use alongside growth would support the funding outlook; another quarter of elevated working-capital outflows and capital spending would weaken it.
- Monitor therapeutics sales, gene shipments and purchasing customers: Continued gains would support the higher-value product strategy; slowing activity would challenge its growth premise.
Figures are computed from the filing's XBRL data; the summary and scores are written by an AI model reading the filing.
Model 005 · prompt 9e47f58d3c